Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ergocalciferol
Drug ID BADD_D00794
Description Ergocalciferol is an inactivated vitamin D analog.[A177526] It is synthesized by some plants in the presence of UVB light.[T577] The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.[T580] Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism.[A177637] The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.[L6058]
Indications and Usage Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.[FDA label] Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.[L6082] Rickets is a condition produced due to a deficiency in vitamin D, calcium or phosphorus. However, this condition can also be related to renal diseases. It is characterized to present weak or soft bones.[A177664] Familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin D metabolism in the kidneys. The presence of this condition can derive in the presence of osteomalacia, bone softening and rickets.[L6085]
Marketing Status approved; nutraceutical
ATC Code A11CC01
DrugBank ID DB00153
KEGG ID D00187
MeSH ID D004872
PubChem ID 5280793
TTD Drug ID D06JPB
NDC Product Code 49452-2760; 66499-0041; 43063-711; 51407-143; 51655-774; 62135-439; 70934-252; 71335-1699; 42291-266; 63187-519; 68071-3444; 68788-7627; 71610-712; 63629-2447; 10888-8131; 64380-737; 68071-1951; 70518-1878; 71335-1449; 10888-0140; 11014-0052; 68071-2352; 71610-552; 72789-249; 51364-0007; 65655-0002; 30698-493; 64980-157; 69452-151; 11014-0026; 50090-4382; 60760-152; 63187-064; 70518-0177; 71610-240; 23155-809; 63629-8144; 68071-2295; 43353-219; 43353-238; 50268-297; 60687-500; 62332-464; 63629-7942; 71335-0062; 71335-0278
UNII VS041H42XC
Synonyms Ergocalciferols | Calciferols | Vitamin D 2 | Vitamin D2 | D2, Vitamin | Ergocalciferol
Chemical Information
Molecular Formula C28H44O
CAS Registry Number 50-14-6
SMILES CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vitamin D deficiency14.12.03.0030.001846%Not Available
Vomiting07.01.07.0030.009301%
Weight decreased13.15.01.005--
Wheezing22.03.01.0090.001505%
Mental status changes19.07.01.0010.001368%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.002530%Not Available
Multiple sclerosis relapse17.16.01.0030.001368%Not Available
Poor venous access24.03.02.0170.002325%Not Available
Peripheral swelling02.05.04.015; 08.01.03.0530.003898%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000684%
Sudden cardiac death08.04.01.008; 02.03.04.0160.000684%Not Available
General physical health deterioration08.01.03.0180.001710%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.002872%Not Available
Dry gangrene24.04.03.018; 23.06.06.0030.000684%Not Available
Intervertebral disc protrusion15.10.01.0040.001368%Not Available
Scleral haemorrhage24.07.05.009; 06.07.01.0020.000684%Not Available
Deep vein thrombosis24.01.02.0030.002188%Not Available
Pulmonary calcification22.01.02.019--Not Available
Vascular calcification24.03.02.013--Not Available
Eye pruritus06.04.05.0060.001505%Not Available
Musculoskeletal stiffness15.03.05.0270.002667%Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.006497%Not Available
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.0070.000684%
Foetal death18.01.02.003; 08.04.01.0110.000684%
Haemorrhage24.07.01.0020.001368%Not Available
Faecaloma07.01.03.0040.000684%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000684%
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.001505%Not Available
Dermatitis psoriasiform23.03.14.0040.001505%Not Available
Heart valve calcification02.07.02.005--Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages